How Long Does Semaglutide Stay Active in the Body

Why a one-week half-life matters more than it sounds

Half-life is the time it takes for the concentration of a drug in your blood to fall by half. For semaglutide, that figure sits at around seven days. Run the arithmetic and you find that after five half-lives (roughly five weeks) only about three percent of a single dose remains in circulation. In practice, this means that if you stop taking Wegovy, you won't feel the effects vanish overnight; the medicine winds down gradually across a month or more.

This slow exit is not accidental. Semaglutide is engineered with a fatty-acid side chain that binds tightly to albumin in the blood, protecting it from breakdown and extending its presence dramatically compared with earlier GLP-1 analogues. The result is a medicine that stays active long enough to suppress appetite around the clock on a single weekly dose. You can read the clinical pharmacology in the Wegovy SmPC on the eMC, which carries the full detail a prescriber or pharmacist would reference.

There is also a practical implication if you miss an injection. Because levels fall slowly, one late dose (within five days of when it was due) typically has a smaller impact on the week than it would with a shorter-acting medicine. Beyond five days, the guidance in the Patient Information Leaflet takes over; your prescriber can advise on the specifics for your situation. If you want a broader picture of how long semaglutide lasts and how timing affects the treatment, our guide to how long semaglutide stays in the body goes further.

How accumulation shapes early results (and why patience is part of the plan

Because each weekly dose adds to the one before it until the body's elimination rate catches up, it takes four to five weeks of consistent dosing to reach what pharmacologists call steady state) the point at which the amount entering the body each week roughly equals the amount cleared. Before steady state, concentrations are still climbing, and the appetite-suppressing effect is still building. This is a large part of why most people do not feel a dramatic change after the first injection.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks at the 2.4mg maintenance dose and recorded an average weight reduction of around 15 percent. That outcome accumulated over more than a year, not in the first month. Weight loss tended to be most rapid in the middle months of the trial, after dose titration was complete and steady-state concentrations were established. Understanding this arc helps set realistic expectations, the half-life is not just a pharmacology detail; it is the timetable your results are built on.

How quickly you personally notice effects also depends on factors beyond pharmacokinetics: your starting dose, how your body tolerates titration, your diet during treatment, and individual metabolic variation. For context on what the results data shows across different people, the evidence on Wegovy results covers the trial findings in more depth. You might also find it useful to read about how long Wegovy takes to work once you start.

What happens after stopping, and what it means for long-term planning

This is the decision most people are actually wrestling with when they search this question. Stopping semaglutide does not immediately undo the weight lost, but it does set a clock running. As concentrations fall over the five weeks after the last injection, GLP-1 receptor activity returns toward baseline, appetite regulation shifts, and (for most people) weight gradually returns. Studies following participants after the STEP trials found that a substantial proportion of weight lost was regained within a year of stopping, without ongoing lifestyle support.

The NHS medicines page for semaglutide notes that treatment is usually long-term, and the NICE recommendation for Wegovy (TA875) sets a maximum of two years within a specialist weight management service for NHS use, a constraint that reflects both the evidence base and resource considerations, not a pharmacological ceiling. Private prescribing decisions are made individually by the prescriber at each clinical review.

None of this means stopping is the wrong call, circumstances change, tolerability varies, and some people achieve lasting lifestyle changes during treatment that alter the trajectory after stopping. What it does mean is that the timing and manner of stopping is worth discussing with your prescriber rather than deciding unilaterally. The guide on how long semaglutide stays in your system covers the clearance timeline in closer detail if you're planning ahead. And if you are considering whether treatment is right for you at all, our weight-loss treatments overview sets out what is licensed and available in the UK.

At nume, every repeat order is reviewed by a real prescriber before anything is dispensed. That is also the right moment to raise questions about duration, dose, or what stopping might mean for you. If you'd like to know more about how the service works, our about page has the detail. To check whether you're eligible, a free consultation takes a few minutes to complete, no referral needed, reviewed the same working day.

A note on cost: private treatment pricing varies by dose and provider, and is worth understanding alongside the clinical picture. Our guide to getting Wegovy in the UK covers what to expect on that front.